Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket
NoticeFDA-2015-N-3469-0001
Comments
51
Last activity May 11, 2026
Deadline
8632 days
Closes Feb 22, 2050
Net supportiSupport minus oppose · campaigns included
+10%
+10% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket
- Posted
- Oct 27, 2015
- Comment period
- Oct 27, 2015 – Feb 22, 2050
- FR Doc
- 2015-27270
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
+10%
Net support
Support28Oppose23
Aggregates include form-letter campaigns. Excluding them, net support is +10% across organic comments.
Who commented
Breakdown by commenter type.
Academic
1
Business
26
Government
1
Individual
14
Trade association
5
Advocacy
4
Comments over time
Weekly arrivals, stacked by stance.
Posted Oct 27, 2015Deadline Feb 22, 2050
Dec 7Jun 4Jan 14Oct 24Oct 21Jun 9May 11
Support28Oppose23Other0
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Business
38%
62%
0%
Individual
71%
29%
0%
Trade association
100%
0%
0%
Advocacy
50%
50%
0%
Academic
100%
0%
0%
Government
0%
100%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Clinical need interpretation11
Compounded weight loss medications7
Compounded peptide access5
Bulk api use for 503b2
Nomination of succinylcholine chloride2
Compounding of thymosin alpha-11
Inclusion of inactive ingredients1
Mitomycin compounding safety1
Nomination of alpha lipoic acid1
Nomination of ashwagandha root extract1
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.